Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next

Viking Therapeutics recently initiated a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist for obesity, following FDA clearance of its investigational new ...
Seeking Alpha

Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens

Lian indicated the oral VK2735 program is expected to advance into Phase III for obesity, with initiation targeted for the third quarter of 2026. "We currently expect to initiate this program in the ...
Nasdaq

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...
Hosted on MSN

Viking advances new amylin-based weight-loss drug into human trials

Viking Therapeutics Inc. VKTX announced on Wednesday that it has initiated a Phase 1 trial evaluating VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA) being developed for ...